India Renews CEPI Partnership To Boost Vaccine R&D Capacity

08 Dec 2025 CW Team

CEPI is a global multi-stakeholder coalition that brings together public, private, philanthropic and civil organisations to accelerate vaccine development for emerging infectious diseases and ensure timely access during outbreaks. As of March 2025, its supporters include several national governments, the European Commission, and philanthropic bodies such as the Bill & Melinda Gates Foundation and the Wellcome Trust.

Since 2019, DBT and BIRAC have collaborated with CEPI on vaccine research targeting diseases with epidemic potential. Major achievements of this partnership include early-stage development of vaccine candidates for chikungunya, coronavirus and monkeypox; establishment of shared research infrastructure such as a bioassay laboratory and an experimental animal facility; and extensive capacity-building programmes.

The DBT–BRIC–THSTI bioassay laboratory and the associated animal facility have been recognised by CEPI as part of its Centralised Lab Network and Animal Lab Network respectively, making them important national assets for vaccine development. The bioassay lab has supported multiple Indian and global vaccine candidates from pre-clinical stages through to phase-3 efficacy trials. Training programmes in vaccine development and clinical research have further strengthened national capability.

The renewed Engagement Strategy broadens the scope of cooperation to include research and development of allied biomedical technologies, such as monoclonal antibodies. The partnership will also cover pathogens listed under the WHO R&D Blueprint for priority diseases.

Renewing the strategy marks a significant step in enhancing India’s preparedness for pandemics by combining CEPI’s technical expertise with India’s growing scientific capabilities. The collaboration will help strengthen critical research infrastructure, expand skilled human resources and support rapid and effective responses to emerging health threats. It also aligns with national development priorities and Sustainable Development Goals relating to good health and well-being.

The Department of Biotechnology (DBT), Ministry of Science and Technology, along with its public sector undertaking, the Biotechnology Industry Research Assistance Council (BIRAC), has renewed its Engagement Strategy with the Coalition for Epidemic Preparedness Innovations (CEPI). The renewed agreement, signed on 18 September 2025, extends the partnership first established in October 2019 for cooperation on vaccine and allied technology research, development and innovation. The Union Cabinet has noted and accepted the renewal. CEPI is a global multi-stakeholder coalition that brings together public, private, philanthropic and civil organisations to accelerate vaccine development for emerging infectious diseases and ensure timely access during outbreaks. As of March 2025, its supporters include several national governments, the European Commission, and philanthropic bodies such as the Bill & Melinda Gates Foundation and the Wellcome Trust. Since 2019, DBT and BIRAC have collaborated with CEPI on vaccine research targeting diseases with epidemic potential. Major achievements of this partnership include early-stage development of vaccine candidates for chikungunya, coronavirus and monkeypox; establishment of shared research infrastructure such as a bioassay laboratory and an experimental animal facility; and extensive capacity-building programmes. The DBT–BRIC–THSTI bioassay laboratory and the associated animal facility have been recognised by CEPI as part of its Centralised Lab Network and Animal Lab Network respectively, making them important national assets for vaccine development. The bioassay lab has supported multiple Indian and global vaccine candidates from pre-clinical stages through to phase-3 efficacy trials. Training programmes in vaccine development and clinical research have further strengthened national capability. The renewed Engagement Strategy broadens the scope of cooperation to include research and development of allied biomedical technologies, such as monoclonal antibodies. The partnership will also cover pathogens listed under the WHO R&D Blueprint for priority diseases. Renewing the strategy marks a significant step in enhancing India’s preparedness for pandemics by combining CEPI’s technical expertise with India’s growing scientific capabilities. The collaboration will help strengthen critical research infrastructure, expand skilled human resources and support rapid and effective responses to emerging health threats. It also aligns with national development priorities and Sustainable Development Goals relating to good health and well-being.

Infrastructure Transport

12 Jan 2026

Dhalbhumgarh Airport Faces 150-km Rule Hurdle

The issue has resurfaced following a recent statement by Union Civil Aviation Minister Ram Mohan Naidu, who said that under existing aviation policy, a new greenfield airport is generally not permitted within an aerial distance of 150 kilometres of an operational civilian airport. He added, however, that if a formal proposal is submitted, its impact on the existing airport can be examined and relaxations may be considered on a case-by-case basis. While the clarification has revived some hope for Dhalbhumgarh, it has also underlined the scale of the technical challenge facing the project. Unde..

Infrastructure Transport

12 Jan 2026

Stakeholders Seek Parallel Ops For Vizag Airports

With road and metro rail links to Bhogapuram still several years away, stakeholders in north Andhra Pradesh have renewed demands to continue civil operations at INS Dega even after the commissioning of Bhogapuram International Airport. The new airport is expected to begin commercial operations from June. Officials said close to 80 per cent of the airport infrastructure at Bhogapuram, including the terminal building and internal approach roads, has already been completed. However, inadequate external connectivity remains a key concern. Making a case for parallel operations, Andhra Pradesh Air ..

Infrastructure Transport

12 Jan 2026

Govt To Roll Out V2V Tech To Cut Road Crashes

In an effort to curb road accidents, particularly in low-visibility conditions such as dense fog, the government is set to roll out vehicle-to-vehicle (V2V) communication technology that will allow cars to exchange real-time data and alert drivers to potential dangers. The announcement was made by Union Road Transport and Highways Minister Nitin Gadkari after the 43rd meeting of the Transport Development Council. The technology involves installing an on-board unit (OBU) in vehicles, enabling wireless data exchange between nearby cars. This will allow vehicles to share information such as spee..